📊 Backtest📒 Journal Updated 29/09/2026
← ⚡ Catalyst
📐 Simulate Position
STALE?Report written 7 days ago · at $7.56entry levels may be stale — re-check before acting

RGNX

Speculative
REGENXBIO Inc. · NASDAQ · Healthcare / Gene Therapy (Multi-Asset AAV Platform)
$7.56
▲ 1.20%
MCap ~$500M
⚠️ CATALYST CORRECTION: today's earlier RGNX report (also dated Sep 29, written before this refresh) used $8.62 and framed NAVSUNLI resubmission as imminent — that was wrong. Live price is $7.56 (-12.3% vs that draft). Independent research for this refresh surfaced a Aug 24, 2026 FDA clinical hold on RGX-121 that the prior draft never incorporated.
BusinessAAV gene therapy developer · RGX-121/NAVSUNLI for MPS II now on FDA clinical hold with no near-term resubmission expected — but RGX-202 (Duchenne) already met its Phase III primary endpoint and BLA submission is guided for this quarter, plus a partnered retina program (ABBV-RGX-314) with positive 3-year durability data
Thesis

⚠️ THESIS BROKEN (catalyst pivot, not a full washout): the prior report's near-term catalyst — an imminent NAVSUNLI (RGX-121) BLA resubmission by end of Q3 2026 — is void. On Aug 24, 2026, the FDA placed a clinical hold on RGX-121 after asymptomatic spinal MRI findings (small nodules/cystic masses, characterized as nonserious/likely benign) turned up in 5 trial participants dosed 3-6 years earlier; REGENXBIO stated it 'does not expect to resubmit the RGX-121 BLA in the near term.' That specific catalyst is dead for this cycle. The real near-term catalyst is a different pipeline asset: RGX-202 for Duchenne muscular dystrophy already met its Phase III AFFINITY DUCHENNE primary endpoint with high statistical significance in Q2 2026, its confirmatory study is fully enrolled ahead of schedule, and management guided a BLA submission this quarter (Q3 2026, ending Sep 30). Analysts have largely held their ground post-clinical-hold — 11 analysts, consensus $23.73 (Strong Buy 6 / Buy 3 / Hold 2), reiterations as recent as Sep 28 (H.C. Wainwright $21) and Sep 25 (Stifel $42) — one analyst called the RGX-121 setback 'disappointing' but said 'larger catalysts remain intact,' referring to RGX-202. Cash runway >$310M pro forma into Q4 2027 reduces near-term financing risk. This is a corrected, more cautious thesis, not a dead one.

📝 Primary Verdict · Core Holding
SPECULATIVESpeculative

Measured median at-catalyst return across the core lane is -6.9% (n=54) — buying at today's $7.56 is not the default entry; the $6.40-6.80 zone is preferred. This is a corrected thesis, not a broken one: the specific catalyst this pick was built on (NAVSUNLI resubmission) is void near-term, but RGX-202's Phase III win and this-quarter BLA guidance is a real, still-intact near-term catalyst that analysts have largely kept faith in post-setback.

78
score / 100 ⓘ
⚡ Catalyst
⚖️ RGX-202 Duchenne BLA Submission~1 DAY

Management guided on the Q2 2026 earnings call that the Duchenne BLA submission is planned 'this quarter' (Q3 2026, ending Sep 30). Phase III AFFINITY DUCHENNE already met its primary endpoint with high statistical significance; the confirmatory study is fully enrolled ahead of schedule. Exact submission day not company-confirmed.

Q3 2026 (by Sep 30)
👁️ ABBV-RGX-314 Wet AMD Pivotal Topline Data~Q4 2026

Partnered with AbbVie. Pivotal-trial topline data for wet AMD expected Q4 2026, alongside an actively enrolling NAAVIGATE Phase IIb/III trial in diabetic retinopathy — where REGENXBIO just reported positive 3-year durability data (Sep 24, 2026): 60% of long-term participants achieved a >2-step DRSS improvement without additional treatment.

Q4 2026
🎯 Entry Point
Entry 1
$7.56
Current priceNow
Entry 2PREFERRED
$6.4–6.8
Post-clinical-hold consolidation zoneIf dips
Entry 3
$5.30
Deep dip / near bear caseIf broader biotech sells off or RGX-202 submission slips
✅ Take Profit
TP1
Base case — RGX-202 BLA submitted on schedule this quarter, no further RGX-121-style surprises; Base assumes the multi-month path through submission, not the 14-day North Star window
$10.58
+40%
TP2
Bull case — RGX-202 submission confirmed plus continued accelerated-approval alignment, approaches BofA's conservative $15 target
$14.36
+90%
TP3 🌙
Moon case — RGX-202 approval pathway de-risks further and retina program delivers, full re-rate toward consensus · 2027
$23.44
+210%
🔴 Stop Loss
Tight Stop
Wider than the regulatory_approval bucket's medianMAE (-9.3%, n=6) — widened further given the added RGX-121 program-impairment uncertainty
$6.05
-20%
Hard Stop
Matches the bear case — signals the RGX-202 submission itself is slipping or facing new FDA pushback
$4.91
-35%
Risk / Reward
Tight stop vs TP2, off current price
5.8 : 1
⚠ Still a strong R/R, but genuinely wider stop than before given the confirmed setback
📅 Estimate Date
FDA Clinical Hold on RGX-121 (realized)
Spinal MRI findings in 5 long-term dosed patients; company does not expect near-term BLA resubmission
Aug 24, 2026
RGX-202 Duchenne BLA Submission
Company-guided window; Phase III primary endpoint already met
Q3 2026 (by Sep 30)
ABBV-RGX-314 Wet AMD Pivotal Topline Data
Partnered with AbbVie; diabetic retinopathy arm shows positive 3-year durability
Q4 2026
📈 Stock Timeline
3 snapshots · Jul 22 → Sep 29
Score
▼ 28
48
Jul 22Sep 29
TP2 Target
▼ 9
$14.36
Jul 22Sep 29
Rank
▲ 2
#30
Jul 22Sep 29
📈 Possible Up % — Scenario Spread
Bear
-35%
$4.91
Base
+40%
$10.58
Bull
+90%
$14.36
Moon
+210%
$23.44
← downsideupside →
🏛️ Fed / Macro Risk — MEDIUM

Assesses how Fed policy / interest rates / inflation affect this stock — LOW = minimal risk, HIGH = proceed with caution

Rate Outlook
Fed hiked to 3.75-4.00% on Sep 16, 2026 (first hike since 2023); next FOMC Oct 27-28, 2026 — after the RGX-202 BLA-submission window.
Inflation
Inflation-driven hike; REGENXBIO's >$310M pro forma cash runway into Q4 2027 meaningfully cushions financing risk versus a pure cash-burning biotech.
Sector Impact
Ultra-rare/multi-asset gene therapy names trade on binary regulatory catalysts more than macro data, but a hawkish Fed still compresses the small-cap biotech multiple broadly.
Summary
MEDIUM macro risk — the multi-year cash runway reduces near-term financing dependency, but this remains a small-cap name sensitive to broad risk-off moves, now compounded by real program-specific setback risk on RGX-121.
🎯 Analyst Targets

Wall Street price targets vs the current price — cross-check our TP levels

Stifel Nicolaus
Buy$42+456%
Consensus (11 analysts)
Buy$23.73+214%
H.C. Wainwright
Buy$21+178%
Bank of America
Buy$15+98%
current price $7.56
🔍 Similar-Catalyst Comparable Check

Stocks that went through similar catalyst events — calibrate whether the +30%+ target is realistic

RGNX❌ BadAug 2026
-12%
in 5 days
FDA places clinical hold on RGX-121 after spinal MRI findings in long-term dosed patients
The event this refresh corrects for — same company, direct precedent for how much this stock moves on genuine program-level regulatory setbacks
RGNX✅ GoodJul 2026
+15%
in 1 day
FDA Type A meeting confirms no additional RGX-121 studies needed (now superseded by the Aug 24 clinical hold)
Illustrates the range of reaction to REGENXBIO regulatory news, though this specific outcome was later overtaken by events
AGIO✅ Good2026
+20%
in 1 day
Mitapivat sickle cell PDUFA process — comparable ultra-rare-disease gene/biologic regulatory pathway
Illustrates the range of outcomes possible when a rare-disease regulatory process concludes positively
⚡ Optional Layer · Tactical Overlay
🎯 Catalyst Spot Mode

Short-term play around the catalyst (Sep 2026 earnings) only — an optional overlay, not a verdict that ranks equal to the Core Holding.

⚠️

Use this stop-loss set (-20% / -15%) only when trading the earnings spot — not for the core holding (use the -20% / -35% set above). If you are holding long-term, follow the core set.

📈Pre-Catalyst Run-up Pattern
n/a (post-setback reset)N/A this cycle — sentiment reset first

REGENXBIO's stock reacted negatively and immediately to the Aug 24 clinical-hold news; no meaningful pre-runup has built yet into the RGX-202 BLA-submission window since the market is still digesting the RGX-121 setback

🎲Historical Post-Catalyst Move
✅ Catalyst Winavg +15%
range: +8% to +25%· Jul 2026
REGENXBIO's own Jul 2026 Type A meeting news (a DIFFERENT, now-void catalyst) drove a positive reaction when it looked like good regulatory news; the regulatory_approval bucket in skill-feedback shows a median excess of +3.3pp vs SPY (n=6). A clean RGX-202 BLA submission this quarter would likely produce a similar modest positive move, not a re-rate on its own — approval itself is the bigger event, still quarters away.
❌ Catalyst Missavg -12%
range: -8% to -20%· Aug 2026
REGENXBIO's own Aug 24, 2026 clinical-hold reaction on RGX-121 is the direct precedent for how this stock reacts to genuine bad regulatory news on one of its programs.
💼Spot Position Sizing
How the recommended % is derived
2%
of portfolio

Cut from 3% in the same-day draft — one of three pipeline programs just took a real regulatory hit, and while RGX-202 remains intact, conviction should reflect the confirmed setback, not just the surviving optionality

🛑Stop Loss · Spot Trade
Spot cut-loss levels — separate from the core holding
Before Catalyst
-20%($6.05)
Below this, the market is pricing a slip in the RGX-202 submission itself or a second program-level setback
After Catalyst (Bad Result)-15%
If RGX-202 submission slips past Q3 2026 or the FDA raises new concerns on it, exit on confirmation
📎 Sources

Generated 2026-09-29 · Not financial advice